Evoke Pharma (EVOK) Stock Analysis

What Evoke Pharma does

Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.

Key metrics

ETFs linked to EVOK

Broad-market and Healthcare sector ETFs an investor holding Evoke Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EVOK fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Evoke Pharma?

Evoke Pharma trades under the ticker EVOK on NASDAQ.

Which exchange is EVOK listed on?

EVOK is listed on NASDAQ.

What sector does Evoke Pharma operate in?

Evoke Pharma is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze EVOK in a portfolio?

PortView shows EVOK's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.